No Data
No Data
Novo-Nordisk A/S (NVO.US) is investing 1.2 billion USD to build a new factory in Odense, Denmark, expected to be completed in 2027.
Novo-Nordisk A/S will invest 8.5 billion Danish Kroner (approximately 1.2 billion US dollars) to build a large factory in Denmark to meet the growing market demand for its blockbuster Pharmaceuticals.
Express News | Novo-Nordisk A/S acquisition of Catalent Trade has been approved for completion.
Novo-Nordisk A/S (NVO.US) invests 1.2 billion USD to build a factory for rare disease drugs in Denmark.
The Danish pharmaceutical company Novo-Nordisk A/S (NVO.US) announced on Monday that it will invest 8.5 billion kroner (approximately 1.2 billion USD) to build a new factory in Odense, Denmark, for the production of drugs for rare diseases. The company stated that construction work has already begun and is expected to be completed by 2027, at which time the facility is projected to create 400 permanent jobs.
Top Midday Stories: Honeywell Mulls Separation of Aerospace Business; Starbucks Expands Parental Leave for US Store Workers
Why the Investor Craze for Ozempic and Rival Weight-loss Drugs May Resume Next Year
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent